Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Xspray Pharma in connection with a directed share issue (3)
Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

October 23, 2020 Capital Markets and Public M&A

Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed share issue, whereby Xspray receives gross proceeds of approximately SEK 265 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. The purpose of the share issue is inter alia to enhance the company’s financial position ahead of negotiating a deal pertaining to its lead product HyNap-Dasa and to continue to expand the company’s product portfolio.

Vinge’s team has consisted of Dain Hård Nevonen, Linnéa Sellström, Joel Magnusson and Linnea Petersson.

Related

Vinge has advised Gamma Waves on Sportway’s EUR 20 million financing round

 Vinge has acted as legal adviser to Gamma Waves in connection with Sportway’s EUR 20 million financing round. The round was led by Gamma Waves, together with continued participation from existing shareholders, and values Sportway at approximately EUR 92 million (around SEK 1 billion) post-money.
June 24, 2026

Vinge advises Spotlight Group in connection with offer from Kriptown

 Vinge is advising Spotlight Group AB (publ) in connection with Kriptown SAS having made a public cash takeover offer to the shareholders of Spotlight Group
June 17, 2026

Vinge has advised EQT IX in connection with its exit of Beijer Ref AB (publ)

 Vinge has advised EQT IX (”EQT”) in connection with the sale of all of its remaining shares of series B in Beijer Ref AB (publ) through an accelerated bookbuilding process carried out on 15 June 2026.
June 16, 2026